New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, ...

Autonomix Medical is focused on developing precision nerve-targeted treatments using a transvascular RF denervation platform. The company’s approach aims to address pancreatic cancer pain, which ...

Autonomix Medical Inc (NASDAQ:AMIX) jumped nearly 14% in premarket trading on Friday after the company released encouraging ...

Biohaven Ltd. recently reported that its Phase 2 proof-of-concept trial of BHV-7000 for major depressive disorder failed to meet the primary MADRS endpoint over six weeks versus placebo, although the ...

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein, which is ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Scientists created a serum containing extracts from a tropical plant and specialized proteins that support hair follicle ...

Biohaven (BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder, or MDD. The study did not meet its primary endpoint, a ...